Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis (Q46987043)

27 December 2017

meta-analysis

0 references

title

Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis (English)

1 reference

27 December 2017

0 references

1 reference

1 reference

4

John P A Ioannidis

1 reference

27 December 2017

Georgia Salanti

2

0 references

author name string

Vassilis Golfinopoulos

series ordinal

1

1 reference

27 December 2017

Nicholas Pavlidis

series ordinal

3

1 reference

27 December 2017

publication date

20 September 2007

1 reference

27 December 2017

Lancet Oncology Commission

published in

1 reference

27 December 2017

volume

8

1 reference

27 December 2017

page(s)

898-911

1 reference

27 December 2017

issue

10

1 reference

27 December 2017

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Determination of factors responsible for the declining incidence of colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Effective surgical adjuvant therapy for high-risk rectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Simultaneous comparison of multiple treatments: combining direct and indirect evidence.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

A comparison of handsearching versus MEDLINE searching to identify reports of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Quantifying heterogeneity in a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Indirect comparisons of competing interventions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Network meta-analysis for indirect treatment comparisons

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Indirect comparisons: the mesh and mess of clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Onco

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic O

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Tri

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Systemic therapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Randomized trials stopped early for benefit: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

Predictive modeling and heterogeneity of baseline risk in meta-analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970281-4

7 January 2021

10.1016/S1470-2045(07)70281-4

Identifiers

DOI

1 reference

27 December 2017

PubMed ID

17888735

1 reference

27 December 2017